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[ ]Announcement  of diagnosis and quality approach in CF 
L. Gu6ganton 1 , G. Rault 1,2.1 Coordination cell of the CF Western Health Network, 
Roscof/~ 2Adult and Pediatric CF Cente~ Roscofj, France 
The announcement of a diagnosis is always a critical period for the patient- 
caregiver elationship, in particular concerning CE It's an announcement of  an 
asymptomatic but serious and incurable illness which requires intensive treatment. 
This announcement is always traumatic, but the method of announcement can 
aggravate or alleviate the trauma. The announcement must not be improvised and 
must be an issue of constant concern in order to improve it. Neonatal screening 
already allows for improvement of the context: the stress and resentment due to a 
diagnostic delay are reduced; the possibility of early treatment reassures the parents; 
the non-urgent context permits better preparation of the first meeting between the 
physician and the family. Neonatal screening is extended to all of  France since 2003. 
We will exam how a process of constant improvement of  quality, as described by 
Deming, has been engaged: 
• Plan: identification of the specific problematic to announce an asymptomatic but 
incurable illness; 
• Do: description of an action plan in the shape of recommendations; 
• Study: evaluation (examine the implementation of these measures and the analyze 
the deviations); 
• Act: proposition of corrective measures and innovative actions. 
The 2 first steps have been accomplished and now, we have to cross the next 2 
steps. We will comment on how the different actors can join their reflexions for an 
innovative and federating project: Evaluation of  CF announcement practices (after 
neonatal screening) in relation with the recommendations. 
12. Screening S107 
~ Severe and mild CFTR genotypes: age and presenting symptoms 
in patients diagnosed through newborn screening versus 
clinical symptoms 
A. Munck 1, C. Sahler 1 , M. Desgeorges 1 , M.L. Briard 1 , J.P. Farriaux 1, G. Bellis 2, 
S. Ravilly 3. 1AFDPHE, 2INED, 3 VLM, Paris, France 
Newborn screening (NBS) for CF has been implemented on a nation wide basis in 
France in 2002. 
Aim: according to the genotype severe/mild (http://www.genet.sickkids.on.ca/cffr, 
2 mutations from the CF-30 kit), to quantify the diagnosis saving time and iden- 
tify the main presenting symptoms in CF patients diagnosed through NBS/clinical 
symptoms (CS). 
Pstients: CS group from the French National Observatory ONM 1999~001 (exclusion: 
familial CF, antenatal dg, regional NBS, meconium ileus (MI). NBS group from 
the French Association for Neonatal Screening data AFDPHE 2002~004 (exclusion: 
antenatal dg, MI, false negative). Four cohorts in each group were defined according to 
the CF mutation data base S/S (class I, II, III), 508/508, S/iVl (class IV, V), R117H/other. 
Methods: the median age at diagnosis and the main presenting symptoms (failure to 
thrive, digestive and respiratory). 
Results: 
CS/NBS Nb 163/277 age at dg (m) F to thrive % Digestive % Respiratory % 
S/S 148/221 16/1.1 35/32 42/35 63/15 
F508/F508 100/144 12/1.1 35/33 4237 61/15 
S/M 15/56 261/1.2 13/7.5 20/5 73/7.5 
R117H/other 4/36 280/1.5 50/0 25/0.3 75/0.3 
CF patients S/S have been diagnosed on CS at a mean age of 16 m, 63% already had a 
clinical pulmonary involvement meanwhile it concerned only 15% of the NBS. Patients 
with S/M have been diagnosed on CS during the second decade of life due to a milder 
symptomatology, though NBS might be questionable for them. 
Conclusion: Up to 85% of the NBS neonates with a severe genotype started their 
follow up in CF centres before a clinical pulmonary involvement and should benefit 
of the optimal preventive treatment whereas two third of the ones diagnosed on CS at 
16 m had pulmonary symptoms at diagnosed already. 
[ ] P r o c e d u r e  for diagnostic announcement of Cystic Fibrosis by a 
multidisciplinary team 
M. Kerbrat 1'2, A. Dirou 1 , S. Argouach 1, I. Corre 1 , J. Pengam 1, L. Gu6ganton 1'2, 
G. Rault 1'2. 1Adult and Pediatric CF Cente~ Roscof/~ 2Coordination cell of the 
CF Western Health Network, Roscof/, France 
In France, systematic screening at birth for CF is carried out since 2003. Announc- 
ing the diagnosis is one of the main tasks of the CRCM (CF Resource and Treatment 
Centre). At the CRCM, ROSCOFF (Brittany), announcement of diagnosis began at 
the end of 2004. In preparation for this new activity, the multidisciplinary team set 
up a quality-oriented procedure to announce the diagnosis of CF, adapting national 
recommendations to the specific work conditions. This procedure applies only to 
newborns for whom the 2 mutations are identified at screening. We describe the 
procedure and present a document entitled "report on telephone conversation with 
the parents in preparation for a consultation to confirm diagnosis of CF". The 
different steps involved for the child, parents and concerned professionals, present 
at the consultation are also described. 
~CF screened newborns with at least one R117H mutation: 
immunoreactive trypsinogen (IRT) and sweat test values, polyT and 
clinical symptoms 
A. Munck, C. Sahler, J.P. ]:;arriaux. AFDPHE, Paris, France 
Newborn screening (NB S) for CF has been implemented over France (2002-early 2003). 
The program uses an immunoreactive trypsinogen (IRT)/DNA testing for positive 
samples (kit Elucigen CF-30 Orchid ARMS) on dried blood spots at day 3. A 
controversy exists regarding the detection of the R117H as the natural history of these 
patients is not clearly defined; small cohorts demonstrate CF phenotypes from normal 
to moderate mostly during the second decade of life. 
Aim: estimation of the incidence, IRT, sweat chloride (SC) levels and parameters at 
diagnosis of screened CF with R l l7H in comparison to CF without Rl l7H.  
Subjects and Methods: to date (2002-October 2005), we detected 569 CF NBS; among 
them 48 had at least a R117H. Were evaluated the median IRT (cut off initially 60 then 
65 gg/L), SC (borderline 30 59meq/L) values, median age and symptoms (failure to 
thrive, digestive, respiratory) at diagnosis in both groups and the R117H/poly T. 
Results: see the table. 
Number IRT D3(btg/L) Diagnosis (d) SC (meq/L) Symptoms 
CF without Rll7H 521 138 34 98 281 (54%) 
R117H/other 48 88 42 31 3 (6%) 
Over 8.4% of the NBS CF infants had at least one Rl l7H.  Only 1/48 was associated 
with 5T, he was asymptomatic, SC 36. 3/48 were R l l7H/R l l7H all asymptomatic, 
SC 35, 30, 29. Among the 47 7T/9T, 21 with borderline SC were asymptomatic, the 
others had normal SC but 2 had respiratory symptoms (bronchiolitis, atelectasia). 
Conclusion: We conclude that CF infants with one R117H detected through NBS 
are mostly asymptomatic at diagnosis; nevertheless 50% had either an abnormal or a 
borderline SC. They should be all monitored in a CF center (one refusal) with repeated 
SC and clinical evaluation. Only long term follow up will help physicians to better 
understand this cohort. Discussion around the R117H withdrawal from the CF-30 kit 
may be questionable but perhaps too premature. 
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